Almont, 5 mg 98 pcs.

Bronchospasm, Runny nose (rhinitis), Bronchial asthma

Prevention and long-term treatment of bronchial asthma in children, including:

• preventing daytime and nighttime symptoms of the disease (for children 2 years and older);
• Treatment of bronchial asthma in patients with hypersensitivity to acetylsalicylic acid (for children 6 years and older);
• preventing exercise-induced bronchospasm (for children 2 years and older).

Promotion of symptoms of seasonal and year-round allergic rhinitis in children from 2 years of age.

Active ingredient

Composition

Active substance:

Montelukast 5.00 mg (in the form of montelukast sodium 5.20 mg);

Auxiliary substances:

Mannitol 201.20 mg,

microcrystalline cellulose 66.00 mg,

How to take, the dosage

Interaction

Special Instructions

Contraindications

Side effects

Overdose

Symptoms of drug overdose in patients with chronic bronchial asthma when administered at a dose greater than 200 mg daily for 22 weeks and at a dose of 900 mg daily for 1 week have not been identified.

There have been reports of acute montelukast overdose (when administered at least 1 g daily) in the post-marketing period and in clinical trials in adults and children. Clinical and laboratory data in this case indicate that the safety profile of the drug in children, adults and elderly patients is consistent. The most frequent symptoms were thirst, drowsiness, vomiting, psychomotor agitation, headache and abdominal pain.

Treatment: administration of symptomatic therapy.

There are no data on the possibility of excretion of montelukast by peritoneal dialysis or hemodialysis.

Pregnancy use

Similarities